PT-141 vs Somatropin
Overview
PT-141 and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares PT-141 and Somatropin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| PT-141 | Somatropin | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 1.75 mg | 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) |
| Frequency | as needed | daily subcutaneous injection |
| Reported benefits | Enhanced libido, improved sexual function, arousal support | In labeled use, somatropin increases linear growth in children with growth failure from growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small size for gestational age and idiopathic short stature. In adults with diagnosed growth hormone deficiency, professional guidelines describe benefits in body composition, exercise capacity, skeletal integrity and quality-of-life measures, with the largest benefit in the most severely deficient patients. |
| Reported side effects | Nausea, flushing, blood pressure changes | Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions. |
Key differences
Primary use. PT-141 is categorised under Hormonal, while Somatropin falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. PT-141: FDA-approved. Somatropin: FDA-approved.
Dosing. PT-141 is typically dosed at 1.75 mg (as needed). Somatropin is typically dosed at 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).
Can you stack them?
Some protocols combine peptides, but stacking PT-141 and Somatropin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between PT-141 and Somatropin?
- PT-141 and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. PT-141 is FDA-approved for one or more indications, whereas Somatropin is FDA-approved for one or more indications.
- What is PT-141 used for?
- Sexual function peptide.
- What is Somatropin used for?
- Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults.
- Can you take PT-141 and Somatropin together?
- Some users combine peptides within a single protocol, but stacking PT-141 and Somatropin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is PT-141 or Somatropin FDA-approved?
- PT-141 is FDA-approved for one or more indications. Somatropin is FDA-approved for one or more indications.
Read the full articles
- PT-141 — full monograph: mechanism, research, dosing & references
- Somatropin — full monograph: mechanism, research, dosing & references